Bentracimab : Wikipedia, the free encyclopedia

Bentracimab

Medication

None

Legal statusLegal status

Investigational

IdentifiersCAS Number

2260568-31-6

PubChem SID

405226665

DrugBank

DB16659

UNII

1TBM83QR9S

KEGG

D11799

Chemical and physical dataFormulaC₂₀₉₅H₃₂₄₀N₅₆₀O₆₇₄S₁₂Molar mass47440.93 g·mol⁻¹

Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y₁₂ inhibitor and is sold under the brand name Brilinta among others).^[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.^[3]^[4] It is not commercially available.

References

^ "Specialist Pharmacy Service: Bentracimab". National Health Service. 10 January 2021.
^ "EU patients enrolled in REVERSE-IT trial of bentracimab for reversal of antiplatelet effects of ticagrelor". Cardiovascular News. 2021-01-29.
^ Clinical trial number NCT04286438 for "A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)" at ClinicalTrials.gov
^ Makhdoum A, Dhingra NK, Kirubaharan A, Eikelboom R, Luc J, Dagher O, et al. (August 2021). "Ticagrelor use and practice patterns among Canadian cardiac surgeons". Journal of Cardiac Surgery. 36 (8): 2793–2801. doi:10.1111/jocs.15636. PMID 34028081.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone

Human	Burosumab Denosumab
Humanized	Blosozumab^† Romosozumab

Musculoskeletal

Human	Stamulumab^†

Circulatory

Human	Abelacimab Alirocumab Ascrinvacumab^§ Bentracimab^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab^‡ Imciromab^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab^† Lecanemab Erenumab Fasinumab^† Fulranumab Opicinumab
Humanized	Bapineuzumab^† Crenezumab^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab^†